Compare Dell Technologies Inc (DELL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs Merck & Co., Inc. — how do they compare? Dell Technologies Inc trades at $586.28 (market cap $365.31B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Dell Technologies Inc and Merck & Co., Inc. are close in size by market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and Merck & Co., Inc. for 98 Days on average.
| DELL | MRK | |
|---|---|---|
Market Cap | $365.31B | $351.28B |
Volume | 5,121,365 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $588.67 | $156.43 |
52-Week Low | $111.10 | $82.49 |
Typical Hold Time | 57 Days | 98 Days |
Enterprise Value | $388.20B | $398.04B |
Dividend Yield | 0.44% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies trades at $574.74, down 0.73% on the day, with strong bullish momentum driven by AI server demand. The stock shows robust earnings performance with three consecutive quarterly beats and raised 2027 AI revenue guidance to $74 billion. Technical indicators signal bullish momentum while fundamentals reveal strong revenue growth and improving profit margins, though valuation multiples appear elevated.
Outlook remains positive with AI server backlog reaching $95 billion and institutional support, though risks include execution challenges and competitive pressures in the rapidly evolving AI infrastructure market. The stock trades near analyst consensus target of $566.35 with upside potential to $735 based on AI-driven growth prospects.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
